These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 10867960)

  • 21. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
    Johnson BA; Ait-Daoud N; Prihoda TJ
    Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Acamprosate and naltrexone: similar efficacy for relapse].
    Saitz R
    Rev Med Suisse; 2014 Dec; 10(455):2437. PubMed ID: 25752019
    [No Abstract]   [Full Text] [Related]  

  • 23. Does the alcoholic's remedy come in a pill?
    Gordon SM
    Behav Healthc Tomorrow; 2001 Aug; 10(4):SR29-30, SR34. PubMed ID: 11496583
    [No Abstract]   [Full Text] [Related]  

  • 24. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
    Rösner S; Leucht S; Lehert P; Soyka M
    J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: preliminary clinical evidence.
    Ait-Daoud N; Johnson BA; Prihoda TJ; Hargita ID
    Psychopharmacology (Berl); 2001 Feb; 154(1):23-7. PubMed ID: 11292002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research.
    Kranzler HR
    Alcohol Alcohol; 2000; 35(6):537-47. PubMed ID: 11093959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.
    Snyder JL; Bowers TG
    Am J Drug Alcohol Abuse; 2008; 34(4):449-61. PubMed ID: 18584575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occurrence and management of depression in the context of naltrexone treatment of alcoholism.
    Farren CK; O'Malley SS
    Am J Psychiatry; 1999 Aug; 156(8):1258-62. PubMed ID: 10450269
    [No Abstract]   [Full Text] [Related]  

  • 29. Physicians' opinions about medications to treat alcoholism.
    Mark TL; Kranzler HR; Song X; Bransberger P; Poole VH; Crosse S
    Addiction; 2003 May; 98(5):617-26. PubMed ID: 12751979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial.
    Anton RF; O'Malley SS; Ciraulo DA; Cisler RA; Couper D; Donovan DM; Gastfriend DR; Hosking JD; Johnson BA; LoCastro JS; Longabaugh R; Mason BJ; Mattson ME; Miller WR; Pettinati HM; Randall CL; Swift R; Weiss RD; Williams LD; Zweben A;
    JAMA; 2006 May; 295(17):2003-17. PubMed ID: 16670409
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opioid antagonists for the treatment of alcohol dependence.
    Yancey JR; Lumbad J
    Am Fam Physician; 2011 Nov; 84(9):990-2. PubMed ID: 22046937
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacologic approaches to the management of alcoholism.
    Anton RF
    J Clin Psychiatry; 2001; 62 Suppl 20():11-7. PubMed ID: 11584870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do acamprosate or naltrexone have an effect on daily drinking by reducing craving for alcohol?
    Richardson K; Baillie A; Reid S; Morley K; Teesson M; Sannibale C; Weltman M; Haber P
    Addiction; 2008 Jun; 103(6):953-9. PubMed ID: 18482418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Pharmacological treatment of alcohol dependence. Acamprosate and naltrexone offer new approach].
    Berglund M; Balldin J; Bendtsen P; Borg S; Franck J; Gustafsson L; Halldin J; Månsson M; Nilsson LH; Stolt G; Willander A
    Lakartidningen; 1997 Jul; 94(30-31):2645-8. PubMed ID: 9273426
    [No Abstract]   [Full Text] [Related]  

  • 35. Pharmacotherapy of alcohol dependence: a review of the clinical data.
    Mann K
    CNS Drugs; 2004; 18(8):485-504. PubMed ID: 15182219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes.
    Spanagel R; Zieglgänsberger W
    Trends Pharmacol Sci; 1997 Feb; 18(2):54-9. PubMed ID: 9090311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical characterization of use of acamprosate and naltrexone: data from an addiction center in India.
    Basu D; Jhirwal OP; Mattoo SK
    Am J Addict; 2005; 14(4):381-95. PubMed ID: 16188718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The COMBINE SAFTEE: a structured instrument for collecting adverse events adapted for clinical studies in the alcoholism field.
    Johnson BA; Ait-Daoud N; Roache JD
    J Stud Alcohol Suppl; 2005 Jul; (15):157-67; discussion 140. PubMed ID: 16223067
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment.
    Rubio G; Jiménez-Arriero MA; Ponce G; Palomo T
    Alcohol Alcohol; 2001; 36(5):419-25. PubMed ID: 11524308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
    Schmidt LG; Smolka MN
    Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.